OZEMPIC
Feb 03, 2025
OZEMPIC’s New Approval Cements Novo’s Lead in GLP-1 Market
The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease. The approval for chr...
Read More...
Sep 27, 2024
Promising Data from the First Dedicated Kidney Outcomes Trial with GLP-1 Receptor Agonist, Semaglutide, in Patients with Type 2 Diabetes and Chronic Kidney Disease
On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 partic...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
